Brilliant Violet 421™ anti-human CD197 (CCR7) Antibody

Pricing & Availability
G043H7 (See other available formats)
Regulatory Status
Other Names
BLR2, CDw197, EBI1, CMKBR7
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
Human peripheral blood lymphocytes were stained with CD3 FITC and CCR7/CD197 (clone G043H7) Brilliant Violet 421™ (top) or mouse IgG2a, κ Brilliant Violet 421™ isotype control (bottom).
  • G043H7_BV421_1_101111
    Human peripheral blood lymphocytes were stained with CD3 FITC and CCR7/CD197 (clone G043H7) Brilliant Violet 421™ (top) or mouse IgG2a, κ Brilliant Violet 421™ isotype control (bottom).
  • G043H7_BV421_2_101111
Compare all formats See Brilliant Violet 421™ spectral data
Cat # Size Price Save
353207 25 tests ¥47,300
353208 100 tests ¥89,540

CCR7, also known as CD197, is a chemokine receptor that binds CCL19 and CCL21. CCR7 and its ligands link innate and adaptive immunity by affecting interactions between T cells and dendritic cells and their downstream effect. Naïve T cells enter the lymph node through high endothelial venules, which express CCL21. Dendritic cells and macrophages enter the lymph node through afferent lymphatics. The encounter of T cells and dendritic cells in the T cell zone is CCR7-dependent. In addition, during immunological surveillance, B cells recirculate between B-cell-rich compartments (follicles or B cell zones) in secondary lymphoid organs, surveying for antigen. After antigen binding, B cells move to the boundary of B and T zones to interact with T-helper cells; this B cell migration is directed by CCR7 and its ligands. CCR7-positive cancer cell expression has been associated with lymph node metastasis.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Reported Reactivity
African Green, Baboon, Cynomolgus, Rhesus
Antibody Type
Host Species
CCR7-transfected cells
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Product Citations
  1. Ols S, et al. 2020. Cell Reports. 30(12):3964-3971. PubMed
  2. Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed
  3. Jiang XL, et al. 2021. Nat Commun. 12:897. PubMed
  4. Eslamizar L, et al. 2021. NPJ Vaccines. 6:15. PubMed
  5. Cassotta A, et al. 2019. Nat Med. 25:1402. PubMed
  6. Spandan V Shah et al. 2018. Cell reports. 25(10):2766-2774 . PubMed
  7. Karlsson H, et al. 2015. PLoS One. 10: 0144787. PubMed
  8. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  9. Ahmed R, et al. 2020. Cell Rep. 33:108501. PubMed
  10. Mandolesi M, et al. 2021. Cell Reports Medicine. 2(4):100252. PubMed
  11. Pan YG, et al. 2021. Immunity. 54(6):1245-1256.e5. PubMed
  12. Ramaswamy A, et al. 2021. Immunity. 54(5):1083-1095.e7. PubMed
  13. Szabo PA, et al. 2021. Immunity. 54(4):797-814.e6. PubMed
  14. van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed
  15. Wallin J, et al. 2016. Nat Commun. 7:12624. PubMed
  16. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  17. Thompson EA, et al. 2019. Cell Rep. 28:1127. PubMed
  18. Siddiqui I et al. 2019. Immunity. 50(1):195-211 . PubMed
  19. Bovay A, et al. 2020. Hum Vaccin Immunother. 16:3103. PubMed
  20. Azeem W, et al. 2021. Biomedicines. 9: . PubMed
  21. Yu C, et al. 2021. Med (N Y). 2:755. PubMed
  22. Richert-Spuhler LE, et al. 2021. Cell Reports Medicine. 2(6):100322. PubMed
  23. Pais Ferreira D, et al. 2020. Immunity. 53(5):985-1000.e11. PubMed
  24. Grifoni A, et al. 2020. Cell. 181(7):1489-1501.e15.. PubMed
  25. Barcelo H, et al. 2018. Curr Protoc Cytom. 84:e35. PubMed
  26. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  27. Cassotta A, et al. 2020. J Exp Med. 217:00:00. PubMed
  28. Port JR, et al. 2020. J Virol. 94:. PubMed
  29. Bziat V, et al. 2021. Cell. . PubMed
  30. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
  31. Halkias J, et al. 2019. J Clin Invest. 130:3562. PubMed
  32. Marcandalli J et al. 2019. Cell. 176(6):1420-1431 . PubMed
  33. Dai Z, et al. 2022. Signal Transduct Target Ther. 7:85. PubMed
  34. Omer B, et al. 2022. Cancer Immunol Res. 10:512. PubMed
  35. Waddington KE, et al. 2020. Front Immunol. 1.51875. PubMed
  36. Georg P, et al. 2022. Cell. 185:493. PubMed
  37. Neumann B, et al. 2015. J Leukoc Biol. 97:19. PubMed
  38. Rosato PC, et al. 2019. Nat Commun. 10:567. PubMed
  39. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  40. Azeem W, et al. 2020. Front Immunol. 11:438. PubMed
  41. Thyagarajan B, et al. 2018. J Immunol Methods. 463:61. PubMed
  42. Nobs SP, et al. 2017. J Exp Med. 214:3015. PubMed
  43. Abd Hamid M et al. 2019. Cancer Immunol Res. 7(8):1293-1306 . PubMed
  44. Gustafson CE, et al. 2020. JCI Insight. 5:. PubMed
  45. Darrah PA, et al. 2019. NPJ Vaccines. 4:21. PubMed
  46. Fu J, et al. 2021. J Clin Invest. 131:. PubMed
  47. Benner M, et al. 2020. Cell Rep. 32:108204. PubMed
  48. Vadaq N, et al. 2022. iScience. 25:105089. PubMed
  49. Grutza R, et al. 2020. J Immunol. 204:2910. PubMed
  50. Cassotta A, et al. 2020. Eur J Immunol. . PubMed
  51. Gerna G, et al. 2015. J Gen Virol. 96:360. PubMed
AB_10915137 (BioLegend Cat. No. 353207)
AB_11203894 (BioLegend Cat. No. 353208)

Antigen Details

Chemokine receptor, G protein-coupled receptors (GPCR), seven transmembrane receptor.

T cells, B cells, NK, dendritic cells.

The chemokine receptor CCR7 plays a pivotal role in the homing of naïve T cells and regulatory T cells to secondary lymphoid organs, and the migration of dendritic cells into afferent lymphatic vessels.
CCL19 and CCL21.
Cell Type
B cells, Dendritic cells, NK cells, T cells
Biology Area
Molecular Family
CD Molecules, Cytokine/Chemokine Receptors, GPCR
Antigen References

1. Yanagihara S, et al. 1998. J. Immunol. 161:3096.
2. Charo IF, et al. 2006. N. Engl. J. Med. 354:610.
3. Reif K, et al. 2002. Nature 416:94.
4. Nakata B, et al. 2008. Oncology 74:69.
5. Brodie T. et al. 2013. Cytometry A. 6: 530-2. PubMed
6. Graves A.J. et al. 2014. Cytometry A. 7: 576–9 PubMed
7. Moncunill G. et al. 2014. Cytometry A. 12: 995-8 PubMed

Gene ID
1236 View all products for this Gene ID
View information about CD197 on

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Does staining at room temperature or even at 37°C help for checking chemokine receptors expression?

Due to continuous recycling of many chemokine receptors, it may be worthwhile to consider staining at room temperature or at 37°C if the staining at lower temperature (which can potentially reduce receptor turnover) is not optimal.

Other Formats

View All CD197 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-human CD197 (CCR7) G043H7 FC
Alexa Fluor® 488 anti-human CD197 (CCR7) G043H7 FC
Brilliant Violet 421™ anti-human CD197 (CCR7) G043H7 FC
PE anti-human CD197 (CCR7) G043H7 FC
APC/Cyanine7 anti-human CD197 (CCR7) G043H7 FC
Pacific Blue™ anti-human CD197 (CCR7) G043H7 FC
APC anti-human CD197 (CCR7) G043H7 FC
FITC anti-human CD197 (CCR7) G043H7 FC
Alexa Fluor® 647 anti-human CD197 (CCR7) G043H7 FC
PerCP/Cyanine5.5 anti-human CD197 (CCR7) G043H7 FC
Brilliant Violet 605™ anti-human CD197 (CCR7) G043H7 FC
PE/Cyanine7 anti-human CD197 (CCR7) G043H7 FC
Brilliant Violet 711™ anti-human CD197 (CCR7) G043H7 FC
Brilliant Violet 785™ anti-human CD197 (CCR7) G043H7 FC
Brilliant Violet 510™ anti-human CD197 (CCR7) G043H7 FC
Brilliant Violet 650™ anti-human CD197 (CCR7) G043H7 FC
PE/Dazzle™ 594 anti-human CD197 (CCR7) G043H7 FC
Biotin anti-human CD197 (CCR7) G043H7 FC
Purified anti-human CD197 (CCR7) (Maxpar® Ready) G043H7 FC,CyTOF®
PerCP anti-human CD197 (CCR7) G043H7 FC
Alexa Fluor® 700 anti-human CD197 (CCR7) G043H7 FC
APC/Fire™ 750 anti-human CD197 (CCR7) G043H7 FC
TotalSeq™-A0148 anti-human CD197 (CCR7) G043H7 PG
TotalSeq™-B0148 anti-human CD197 (CCR7) G043H7 PG
TotalSeq™-C0148 anti-human CD197 (CCR7) G043H7 PG
Brilliant Violet 750™ anti-human CD197 (CCR7) G043H7 FC
Ultra-LEAF™ Purified anti-human CD197 (CCR7) G043H7 FC,Block
Spark NIR™ 685 anti-human CD197 (CCR7) G043H7 FC
KIRAVIA Blue 520™ anti-human CD197 (CCR7) G043H7 FC
PE/Fire™ 640 anti-human CD197 (CCR7) G043H7 FC
Spark YG™ 581 anti-human CD197 (CCR7) G043H7 FC
APC/Fire™ 810 anti-human CD197 (CCR7) Antibody G043H7 FC
TotalSeq™-D0148 anti-human CD197 (CCR7) G043H7 PG
PE/Fire™ 810 anti-human CD197 (CCR7) Antibody G043H7 FC
PE/Cyanine5 anti-human CD197 (CCR7) G043H7 FC
Spark YG™ 593 anti-human CD197 (CCR7) G043H7 FC
PE/Fire™ 744 anti-human CD197 (CCR7) G043H7 FC
Spark Red™ 718 anti-human CD197 (CCR7) (Flexi-Fluor™) G043H7 FC
Spark PLUS UV™ 395 anti-human CD197 (CCR7) G043H7 FC
Go To Top Version: 2    Revision Date: 04/08/2014

For Research Use Only. Not for diagnostic or therapeutic use.


This product is supplied subject to the terms and conditions, including the limited license, located at ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.


BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.


8999 BioLegend Way, San Diego, CA 92121
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.


Login / Register
Remember me
Forgot your password? Reset password?
Create an Account